Johnson & Johnson (J&J) has gained a series of innovative biosurgical products with its acquisition of Omrix, its partner of five years, for US$438 M. The two companies already have a marketing agreement for Omrix’s flagship product, but with this acquisition, J&J can now use its marketing skills to sell other Omrix products while Omrix focuses on developing novel biosurgical products.